[Preclinical and clinical data of the synthetic Xa inhibitor fondaparinux (Arixtra(®))]

Nihon Yakurigaku Zasshi. 2012 Mar;139(3):117-26. doi: 10.1254/fpj.139.117.
[Article in Japanese]
No abstract available

Publication types

  • Review

MeSH terms

  • Acute Disease
  • Animals
  • Anticoagulants / administration & dosage
  • Anticoagulants / pharmacokinetics
  • Anticoagulants / pharmacology*
  • Clinical Trials as Topic*
  • Disease Models, Animal
  • Drug Evaluation, Preclinical
  • Drug Interactions
  • Drug Therapy, Combination
  • Factor Xa Inhibitors*
  • Fibrinolytic Agents / administration & dosage
  • Fondaparinux
  • Humans
  • Injections, Subcutaneous
  • Polysaccharides / administration & dosage
  • Polysaccharides / pharmacokinetics
  • Polysaccharides / pharmacology*
  • Pulmonary Embolism / drug therapy*
  • Venous Thrombosis / drug therapy*

Substances

  • Anticoagulants
  • Factor Xa Inhibitors
  • Fibrinolytic Agents
  • Polysaccharides
  • Fondaparinux